Tags

Type your tag names separated by a space and hit enter

Dopamine agonists in the treatment of Parkinson's disease.
Expert Rev Neurother. 2006 Jan; 6(1):81-9.ER

Abstract

Dopamine agonists are highly effective as adjunctive therapy to levodopa in advanced Parkinson's disease and have rapidly gained popularity as a monotherapy in the early stages of Parkinson's disease for patients less than 65-70 years old. In the latter case, dopamine agonists are about as effective as levodopa but patients demonstrate a lower tendency to develop motor complications. However, dopamine agonists lose efficacy over time and the number of patients remaining on agonist monotherapy decreases to less than 50% after 3 years of treatment. Thus, after a few years of treatment the majority of patients who started on dopamine agonists will be administered levodopa, in a combined dopaminergic therapy, in order to achieve a better control of motor symptoms.

Authors+Show Affiliations

Department of Neuroscience, University of Pisa, (56126) Pisa, Italy. u.bonuccelli@med.unipi.itNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16466315

Citation

Bonuccelli, Ubaldo, and Nicola Pavese. "Dopamine Agonists in the Treatment of Parkinson's Disease." Expert Review of Neurotherapeutics, vol. 6, no. 1, 2006, pp. 81-9.
Bonuccelli U, Pavese N. Dopamine agonists in the treatment of Parkinson's disease. Expert Rev Neurother. 2006;6(1):81-9.
Bonuccelli, U., & Pavese, N. (2006). Dopamine agonists in the treatment of Parkinson's disease. Expert Review of Neurotherapeutics, 6(1), 81-9.
Bonuccelli U, Pavese N. Dopamine Agonists in the Treatment of Parkinson's Disease. Expert Rev Neurother. 2006;6(1):81-9. PubMed PMID: 16466315.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dopamine agonists in the treatment of Parkinson's disease. AU - Bonuccelli,Ubaldo, AU - Pavese,Nicola, PY - 2006/2/10/pubmed PY - 2006/4/28/medline PY - 2006/2/10/entrez SP - 81 EP - 9 JF - Expert review of neurotherapeutics JO - Expert Rev Neurother VL - 6 IS - 1 N2 - Dopamine agonists are highly effective as adjunctive therapy to levodopa in advanced Parkinson's disease and have rapidly gained popularity as a monotherapy in the early stages of Parkinson's disease for patients less than 65-70 years old. In the latter case, dopamine agonists are about as effective as levodopa but patients demonstrate a lower tendency to develop motor complications. However, dopamine agonists lose efficacy over time and the number of patients remaining on agonist monotherapy decreases to less than 50% after 3 years of treatment. Thus, after a few years of treatment the majority of patients who started on dopamine agonists will be administered levodopa, in a combined dopaminergic therapy, in order to achieve a better control of motor symptoms. SN - 1744-8360 UR - https://www.unboundmedicine.com/medline/citation/16466315/Dopamine_agonists_in_the_treatment_of_Parkinson's_disease_ DB - PRIME DP - Unbound Medicine ER -